Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Open-label, Multicenter, Phase 3 Trial of Ivonescimab Alone or With Ligufalimab Versus Pembrolizumab in First-line Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

NCT07264075 is registered in ClinicalTrials.gov with Groupe Oncologie Radiotherapie Tete et Cou as lead sponsor.

NCT NCT07264075
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07264075 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Open-label, Multicenter, Phase 3 Trial of Ivonescimab Alone or With Ligufalimab Versus Pembrolizumab in First-line Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
Lead sponsor
Groupe Oncologie Radiotherapie Tete et Cou
Phase
Phase 3
Overall status
Recruiting
Start date
May 5, 2026
Completion date
May 31, 2030
Enrollment
780 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

squamous cell carcinoma head and neck cancer (hnscc)